trending Market Intelligence /marketintelligence/en/news-insights/trending/Sgh0GkUoT3XqSfd2g2Newg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alnylam seeking European approval for genetic disease drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Alnylam seeking European approval for genetic disease drug

Alnylam Pharmaceuticals Inc. filed a marketing authorization application to the European Medicines Agency for patisiran to treat adults with hereditary transthyretin-mediated amyloidosis.

Hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis, is an inherited, progressively debilitating, and often fatal disease caused by mutations in the transthyretin gene.

The company's application is under accelerated assessment by the agency, with a reduced evaluation time of 150 days from 210.

Earlier, Alnylam submitted a new drug application for patisiran to the U.S. Food and Drug Administration.

The company said its partner Sanofi Genzyme, Sanofi's specialty care global business unit, is preparing regulatory filings for the drug in Japan, Brazil and other countries, with submissions to commence in the first half of 2018.